ahlam1399
09-27-2016, 02:22 PM
Amgen?s multiple myeloma drug falls short in late stage study
Sept 27 (Reuters) - Amgen Inc said on Tuesday itscancer drug Kyprolis failed to meet the main goal of alate-stage study against Takeda Pharmaceutical Co Ltd's Velcade for treating newly diag**sed multiple myeloma.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=0za39jEQj0E:4kNFi4GQTPE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=0za39jEQj0E:4kNFi4GQTPE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=0za39jEQj0E:4kNFi4GQTPE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=0za39jEQj0E:4kNFi4GQTPE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=0za39jEQj0E:4kNFi4GQTPE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/0za39jEQj0E
Sept 27 (Reuters) - Amgen Inc said on Tuesday itscancer drug Kyprolis failed to meet the main goal of alate-stage study against Takeda Pharmaceutical Co Ltd's Velcade for treating newly diag**sed multiple myeloma.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=0za39jEQj0E:4kNFi4GQTPE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=0za39jEQj0E:4kNFi4GQTPE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=0za39jEQj0E:4kNFi4GQTPE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=0za39jEQj0E:4kNFi4GQTPE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=0za39jEQj0E:4kNFi4GQTPE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/0za39jEQj0E